Ari Green, MD
Dr. Green, Chief of the Division of Neuroinflammation and Glial Biology at the University of California, San Francisco, discusses the development of potential remyelinating therapies and a recent trial of clemastine fumarate in patients with multiple sclerosis and chronic demyelinating optic neuropathy.
SAN DIEGO—A novel therapy designed to promote the maturation and activation of myelin-producing oligodendrocytes is moving to phase II clinical...
John DeLuca, PhDPublish date: June 13, 2018
Global MS trends: A chaotic picture with risk as the central themePublish date: June 2, 2018
Focus on preventing comorbidities in MS, physician urgesPublish date: June 2, 2018
Immunopathogenesis, diagnosis, and treatment of MS